anti-CSF-1

Anti-CSF-1 refers to a class of therapeutic agents, primarily monoclonal antibodies, that target and neutralize the Colony Stimulating Factor 1 (CSF-1) ligand, also known as Macrophage Colony-Stimulating Factor (M-CSF). By binding to CSF-1, these agents prevent its interaction with the CSF-1 receptor (CSF-1R), thereby inhibiting the differentiation, proliferation, and survival of cells in the monocytic lineage, particularly immunosuppressive tumor-associated macrophages (TAMs). In oncology, anti-CSF-1 therapies are investigated for their ability to remodel the tumor microenvironment and enhance the efficacy of other treatments like radiotherapy and checkpoint inhibitors. A notable example of a specific drug in this category is lacnotuzumab (MCS110). These agents are also explored for inflammatory and proliferative conditions such as pigmented villonodular synovitis (PVNS) and tenosynovial giant cell tumor (TGCT).

Other names

anti-CSF-1anti-CSF1anti-CSF 1anti-Colony Stimulating Factor 1anti-M-CSFαCSF-1